Bridge Biotherapeutics Rebounds After IPF Deal Roller Coaster Ride

Multiple R&D Events This Year

 
• By Jung Won Shin

Bridge Biotherapeutics' CEO talks to Scrip about plans for autotaxin inhibitor returned by Boehringer Ingelheim in 2020, as well as other major R&D developments and priorities for this year and beyond.

James Jungkue Lee, President & CEO of Bridge Biotherapeutics
Hopes Revive For U-Turned IPF Contender As Phase II Nears • Source: Bridge Biotherapeutics

More from South Korea

More from Focus On Asia